Market Place
Sourcing Support
Asher Bio Partners With Etakafusp Alfa For SCLC Trials
08 Jan 2025 //
BUSINESSWIRE
Asher Bio To Evaluate Etakafusp Alfa In NSCLC Phase 1b/2 Study
07 Jan 2025 //
BUSINESSWIRE
Asher Bio $55M Series C For Lead Program Phase 1b
16 Apr 2024 //
BUSINESSWIRE
Asher Announces Publications of AB248, its CD8+ T Cell Selective IL-2 Candidate
03 Apr 2024 //
BUSINESSWIRE
Asher drops 60% of staff to zero in on lead immunotherapy
19 Dec 2023 //
FIERCE BIOTECH
Asher Bio Presents Promising New Preclinical Data for AB821 at SITC
31 Oct 2023 //
BUSINESSWIRE
Asher Bio Presents New Preclinical Data Further Supporting Development of AB359
22 Jun 2023 //
BUSINESSWIRE
Asher Bio to Highlight Pipeline Programs in Presentations at AACR Meeting 2023
14 Mar 2023 //
BUSINESSWIRE
Asher Bio Announces Dosing of First Patient in Phase 1a/1b Trial of AB248
17 Jan 2023 //
BUSINESSWIRE
Asher Bio Appoints Independent Director Elaine Sun to Its Board
05 Jan 2023 //
BUSINESSWIRE
Asher Bio Presents New Preclinical Data at SITC 2022 Supporting AB248 and AB821
10 Nov 2022 //
BUSINESSWIRE
Asher Bio Presents New Data Demonstrating Preclinical Proof-of-Concept for AB359
04 Nov 2022 //
BUSINESSWIRE
Asher to Present Data for CAR-T Cell Therapies by Cis-Targeted IL-2 & IL-21
03 Nov 2022 //
BUSINESSWIRE
Asher Bio to Present First Preclinical Data for AB359
21 Oct 2022 //
BUSINESSWIRE
Asher to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies
05 Oct 2022 //
BUSINESSWIRE
Asher Bio Appoints Independent Director Bob Deresiewicz, M.D., to its Board
06 Jul 2022 //
BUSINESSWIRE
Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer
13 Jun 2022 //
BUSINESSWIRE
Asher Bio Announces Trial Collaboration with Merck for AB248+ KEYTRUDA
01 Jun 2022 //
BUSINESSWIRE
Asher Bio to Present PC Data Demonstrating Differentiated Profile of AB248
08 Apr 2022 //
BUSINESSWIRE
Asher Bio to Showcase Continued Progress with Lead Program AB248 at AACR
08 Mar 2022 //
BUSINESSWIRE
Asher Bio Appoints Ian T. Clark to Its Board of Directors
14 Feb 2022 //
BUSINESSWIRE
Asher Bio to Present at Upcoming Investor Conferences
04 Feb 2022 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.